What Are Peptides?

Peptides are short chains of amino acids, acting as a distinct drug modality that often mimics or improves upon the body's natural signaling molecules. Their high target specificity and lower off-target toxicity make them attractive therapeutic agents, with over 80 peptide-based drugs currently in clinical use.

What Are Peptides?

Peptides are sequences of amino acids, typically shorter than proteins, linked by peptide bonds. As a drug modality, they are distinguished from small molecules and biologics. Many therapeutic peptides function by mimicking endogenous signaling molecules or are engineered analogs designed to improve upon natural processes. Their diverse applications span metabolic disease, rare disease, acute care, oncology, and infectious disease, reflecting their ability to target various structures, including G protein-coupled receptors (GPCRs).

How Therapeutic Peptides Work

Therapeutic peptides exert their effects by interacting with specific biological targets, leading to a desired physiologic effect. This can include stimulating insulin secretion, inducing satiety, regulating water retention, suppressing gonadal function, promoting bone anabolism, or controlling symptoms in neuroendocrine diseases. A key advantage of peptides is their strong target specificity, which generally translates to lower off-target toxicity compared to other drug types. However, peptides can be susceptible to rapid degradation by enzymes (proteolysis), poor absorption across membranes, and short half-lives. Modern peptide engineering addresses these challenges through strategies like cyclization, backbone and sequence modifications, lipidation, and the substitution of D-amino acids to enhance stability and extend activity.

Peptide Drugs in Clinical Use

The landscape of peptide therapeutics has expanded significantly, with more than 80 peptide-based drugs now in clinical use. Over 40 of these have received approval in the last decade alone. This growth underscores their increasing importance in modern medicine.

Outlook

The development pipeline for peptides remains robust, with a significant focus on metabolic diseases such as diabetes and obesity dominating Phase 3 clinical trials. Rare diseases and oncology also continue to be major categories for new peptide drug approvals. The ongoing advancements in peptide engineering promise to further enhance their stability, bioavailability, and therapeutic efficacy, solidifying their role as a cornerstone of pharmaceutical innovation.